Impact of Taxanes, Endocrine Therapy, and Deleterious Germline BRCA Mutations on Anti-müllerian Hormone Levels in Early Breast Cancer Patients Treated With Anthracycline- and Cyclophosphamide-Based Chemotherapy

Matteo Lambertini,Nathalie Olympios,Justine Lequesne,Céline Calbrix,Maxime Fontanilles,Agnès Loeb,Marianne Leheurteur,Isabelle Demeestere,Frédéric Di Fiore,Anne Perdrix,Florian Clatot

DOI: https://doi.org/10.3389/fonc.2019.00575

IF: 4.7

2019-07-12

Frontiers in Oncology

Abstract:<span><strong>Background:</strong> Limited evidence exists on the impact of adding a taxane, using endocrine therapy and carrying a deleterious germline <i>BRCA</i> mutation on ovarian reserve measured by anti-müllerian hormone (AMH) levels of young breast cancer patients receiving (neo)adjuvant cyclophosphamide- and anthracycline-based chemotherapy.<strong>Methods:</strong> This is a biomarker analysis including young (≤ 40 years) early breast cancer patients with known germline <i>BRCA</i> mutational status and available prospectively collected frozen plasma samples before and after chemotherapy. Chemotherapy consisted of either six cycles of FEC (5 fluorouracil 500 mg/m², epirubicin 100 mg/m², cyclophosphamide 500 mg/m²) or three cycles of FEC followed by three cycles of docetaxel (D, 100 mg/m²). Endocrine therapy consisted of tamoxifen (±GnRH agonists). AMH levels at baseline, 1 and 3 years after diagnosis were compared according to type of chemotherapy (FEC only vs. FEC-D), use of endocrine therapy (yes vs. no) and deleterious germline <i>BRCA</i> mutations (mutated vs. negative).<strong>Results:</strong> Out of 148 included patients, 127 (86%) received D following FEC chemotherapy, 90 (61%) underwent endocrine therapy, and 35 (24%) had deleterious germline <i>BRCA</i> mutations. In the whole cohort, AMH levels drastically dropped 1 year after diagnosis (<i>p</i> &lt; 0.0001) with a slight but significant recovery at 3 years (<i>p</i> &lt; 0.0001). One year after diagnosis, patients treated with FEC only had higher median AMH levels than those who received FEC-D (0.22 vs. 0.04 μg/L, <i>p</i> = 0.0006); no difference was observed at 3 years (0.06 and 0.18 μg/L, <i>p</i> = 0.47). Patients under endocrine therapy had significantly higher AMH levels than those who did not receive this treatment 1 year after diagnosis (0.12 vs. 0.02 μg/L; <i>p</i> = 0.008), with no difference at 3 years (0.11 and 0.20 μg/L, <i>p</i> = 0.22). AMH levels were similar between <i>BRCA</i>-mutated and <i>BRCA</i>-negative patients at baseline (1.94 vs. 1.66 μg/L, <i>p</i> = 0.53), 1 year (0.09 vs. 0.06 μg/L, <i>p</i> = 0.39) and 3 years (0.25 vs. 0.16 μg/L; <i>p</i> = 0.43) after diagnosis.<strong>Conclusions:</strong> In breast cancer patients receiving FEC chemotherapy, adding D appeared to negatively impact on their ovarian reserve in the short-term; no further detrimental effect was observed for endocrine therapy use and presence of a deleterious germline <i>BRCA</i> mutation.</span>

oncology